Highly effective cervical cancer screening for low income countries

March 3, 2017
Highly effective cervical cancer screening for low income countries
A cytologic smear under the microscope. Credit: Queen Mary, University of London

Cervical cancer is the second most common cancer in women in developing countries, and globally some quarter of a million women die from the disease each year - most of them from low and middle income countries (LMICs).

To reduce the incidence of cervical cancer in developed , nationwide screening is offered to all . Taking a small cluster of cells ('') to diagnose disease before it progresses to cancer has been extremely effective. But in less developed countries, a lack of infrastructure and quality management have hampered widespread implementation of effective screening programmes.

In the first study to evaluate the use of cytology to diagnose cervical cancer in LMICs, the researchers looked at cytology results from 717 cervical cancers from 23 studies in countries including India, Bangladesh, China, Thailand, Kenya, South Africa, Uganda, Peru, El Salvador, Costa Rica, Nicaragua, Brazil, Argentina and Egypt. They argued that cytology in these countries might be used to diagnose cervical cancer earlier.

An excellent screening tool

The researchers found that even in these low-resource settings, cytology was very sensitive and consistent for detecting invasive cancer. Cytology was found to successfully find cancer with 95.9 per cent accuracy in high-risk women showing symptoms.

Corresponding author Dr Alejandra Castanon from QMUL's Wolfson Institute of Preventive Medicine said: "Cytology has long been established as an excellent screening tool to prevent cervical cancer by detecting precancerous lesions. However, little research has been carried out regarding its sensitivity to cancer.

"We've found that this is an excellent tool for targeted screening of populations at high risk of cervical cancer, leading to early diagnosis. In resource-poor settings with limited facilities to treat advanced cancers, this could have a big impact on cervical cancer mortality."

Reducing burden and cost

The researchers say that restricting cytology to symptomatic women and referring only those with severe lesions would lead to substantially fewer women requiring further investigation. This could mean a reduction in burden on resource and cost, and could result in the diagnosis of cervical cancers at an earlier stage to improve overall survival from the disease.

Co-author Professor Peter Sasieni from QMUL's Wolfson Institute of Preventive Medicine added: "The implications are that, even when a country lacks infrastructure to implement a quality-assured cervical programme nationally, it might be able to facilitate early diagnosis of by using cervical cytology, and only referring women with severely abnormal smears."

The study was funded by Cancer Research UK and published in the Journal of Global Oncology.

Explore further: Low incidence of cervical cancer, CIN3+ for HPV-negative women

More information: Alejandra Castanon et al. Systematic Review and Meta-Analysis of Individual Patient Data to Assess the Sensitivity of Cervical Cytology for Diagnosis of Cervical Cancer in Low- and Middle-Income Countries, Journal of Global Oncology (2017). DOI: 10.1200/JGO.2016.008011

Related Stories

Low incidence of cervical cancer, CIN3+ for HPV-negative women

October 7, 2016
(HealthDay)—Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+), which supports an extension of the cervical screening ...

ACOG: New recommendations for cervical cancer screening

December 23, 2015
(HealthDay)—In a practice bulletin published in the January issue of Obstetrics & Gynecology, new recommendations are presented for cervical cancer screening and prevention.

Screening, HPV vaccine can prevent cervical cancer: FDA

February 8, 2017
(HealthDay)—Women can reduce their risk of cervical cancer through vaccination and screening, the U.S. Food and Drug Administration says.

More than two-thirds of cervical cancer deaths prevented by screening

September 19, 2016
Cervical screening prevents 70 per cent of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83 per cent, according to research led by Queen Mary University of London (QMUL).

HPV testing could cut cervical cancers by a third

June 14, 2013
(Medical Xpress)—Testing women for the human papillomavirus (HPV) first, instead of using the traditional cervical screening test to detect abnormal cells in the cervix, could prevent around 600 cases of cervical cancer ...

Recommended for you

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.